“The existing circumstance has uncovered some structural weaknesses during the EU’s medicines supply chain and also a superior dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides stated. She proposed that offer chain concerns be tackled in an EU pharmaceut